-+ 0.00%
-+ 0.00%
-+ 0.00%

MERCK AND MODERNA WILL PRESENT RESULTS FROM LANDMARK PHASE 3 INTERPATH-001 TRIAL FOR INTISMERAN AUTOGENE PLUS KEYTRUDA® (PEMBROLIZUMAB) AT ESMO 2026 PRESIDENTIAL SYMPOSIUM

Reuters·10/22/2026 19:01:04